C0737
Cilostazol
≥98% (HPLC), Phosphodiesterase III (PDE3) inhibitor, powder
Synonyme(s) :
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C20H27N5O2
Numéro CAS:
Poids moléculaire :
369.46
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
Cilostazol, ≥98% (HPLC), powder
Quality Level
assay
≥98% (HPLC)
form
powder
color
off-white
solubility
DMSO: 10 mg/mL, clear
originator
Otsuka Pharma
SMILES string
O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1
InChI
1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChI key
RRGUKTPIGVIEKM-UHFFFAOYSA-N
Gene Information
human ... PDE3A(5139), PDE3B(5140)
General description
Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.
Application
Cilostazol has been used:
- to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
- in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
- to induce adenosine triphosphate (ATP) release in white adipocytes
Biochem/physiol Actions
Phosphodiesterase III (PDE3) inhibitor
Features and Benefits
This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration
Tozzi M, et al.
bioRxiv, 380469-380469 (2018)
Kuang-Yi Tseng et al.
Medicina (Kaunas, Lithuania), 59(3) (2023-03-30)
Background and Objective: Our previous study demonstrated that consistent treatment of oral cilostazol was effective in reducing levels of painful peripheral neuropathy in streptozotocin-induced type I diabetic rats. As diabetic neuropathy is characterized by hyperglycemia-induced nerve damage in the periphery
James J Dinicolantonio et al.
The American journal of cardiology, 112(8), 1230-1234 (2013-07-06)
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. A systematic review and meta-analysis of randomized controlled trials using Ovid